IP Library Granted Patent US 8,808,686
Granted Patent B2
US 8,808,686 · App. 13/236,538 · Granted Aug 19, 2014

Adjuvant-sparing multi-dose influenza vaccination regimen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,808,686
App. No.
13/236,538
Granted
Aug 19, 2014
Kind
B2
Abstract

An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant.

Claims (9)

1. A method for immunizing a patient against influenza virus infection, comprising the steps of:

(i) administering by intramuscular injection a dose of influenza virus vaccine comprising an inactivated influenza antigen in combination with a first adjuvant which comprises an oil-in-water emulsion; and

(ii) administering a further dose of influenza virus vaccine that is unadjuvanted, wherein the further dose is administered by the same route as the first dose.

2. The method of claim 1 , wherein the vaccines include hemagglutinin at less than 15 μg per strain per vaccine.

3. The method of claim 1 , wherein the influenza virus vaccines include an influenza virus antigen from a H1, H2, H3, H5, H7 or H9 influenza A virus subtype.

4. A method for immunizing a patient against influenza virus infection, wherein the patient has previously received a dose of influenza virus vaccine by intramuscular injection comprising an inactivated influenza antigen in combination with a first adjuvant which comprises an oil-in-water emulsion, and wherein the method comprises the step of administering by intramuscular injection to that patient a further dose of influenza virus vaccine that is unadjuvanted.

5. The method of claim 4 wherein the influenza virus vaccines include an influenza virus antigen from a H1, H2, H3, H, H7 or H9 influenza A virus subtype.

6. The method of claim 1 , wherein the administering of step (ii) is within six months after administering the dose in step (i).

7. The method of claim 4 wherein the vaccines include hemagglutinin at less than 15 μg per strain per vaccine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2016
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 039335/0937 →